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ABSTRACT
Objective: To assess the reliability and validity of a Spanish version of the
LDQOL 1.0 (Liver Disease Quality of Life questionnaire).
Methods: Observational, cross-sectional study in Spanish patients await-
ing liver transplantation (LT). Feasibility was assessed by analyzing admin-
istration times and missing responses. Ceiling and ﬂoor effects were
calculated and reliability was tested by examining internal consistency
(Cronbach’s alpha). Convergent validity was tested by examining corre-
lations between LDQOL disease-speciﬁc and Short Form health survey
with 36 questions (SF-36) dimensions. Known groups’ validity was tested
by examining the LDQOL’s capacity to discriminate between groups
deﬁned by etiology and Child–Turcotte–Pugh (CTP) scores.
Results: A total of 200 patients were included for analysis. Mean age (SD)
was 52.6 (9.8) years and 73% of the sample were male. The most common
indication for LT was liver cancer (34%). Mean (SD) time to complete the
questionnaire was 35.8 minutes (21.2 minutes). Missing responses were
highest on the dimensions of sexual functioning and symptoms of liver
disease. Ceiling effects were over 20% on 7 of the LDQOL’s 12 disease-
speciﬁc scales. Cronbach’s alpha coefﬁcients were over 0.70 on all but 2
dimensions. Correlations between SF-36 and LDQOL disease-speciﬁc
dimensions generally fulﬁlled the hypotheses, with 35 of the 40 highest
and lowest correlations (87.5%) being in the expected direction. The
LDQOL discriminated well between patients in CTP class A and C, and as
hypothesized, hepatocarcinoma and alcoholic cirrhosis patients scored
better on most dimensions than patients with hepatitis C virus or other
etiologies.
Conclusions: The Spanish version of the LDQOL 1.0 has shown satisfac-
tory reliability and validity.
Keywords: liver disease, quality of life, questionnaire, validity.
Introduction
Advanced liver disease impacts both patient survival and quality
of life (QOL) [1], although several treatments, including liver
transplants, have been shown to lead to substantial improve-
ments on both of these outcomes [2–4]. The standardized mea-
surement of patients’ health-related QOL (HRQOL) therefore
has an important role to play in the assessment and management
of liver disease patients [5,6]. For that reason, several question-
naires have been developed to measure the impact of liver disease
and its treatment on patients’ HRQOL [7–9]; one of the most
complete of the currently available instruments is the Liver
Disease QOL Questionnaire (LDQOL 1.0) [7].
The LDQOL 1.0 was designed to be a disease-speciﬁc, self-
report measure for patients with advanced, chronic liver disease
[7]. It includes the generic SF-36 health survey as well as 75
disease-speciﬁc items that measure HRQOL in 12 dimensions.
Testing of the original US English version of the questionnaire
showed the instrument to be reliable and valid for use in pre-
transplant liver disease patients and patients submitted for liver
transplant evaluation. A short version of the LDQOL developed
more recently has also proven to be responsive to changes over
time as well as predicting mortality in patients with advanced
liver disease [10,11].
A preliminary validation of an adapted Spanish version of the
LDQOL was performed in posttransplant patients [12], but it
has not been validated for use in pretransplant patients, which
was the original target group for the instrument. It is important
to validate instruments in different populations because the spe-
ciﬁc characteristics of those groups may affect psychometric per-
formance. Likewise, when HRQOL questionnaires are adapted
for use in different languages and cultural contexts, the new
language version will require revalidation to ensure that adapta-
tion has not affected instrument performance [13,14].
Earlier studies with the LDQOL found that there was only a
low to moderate correlation between LDQOL 1.0 scores and
clinician-derived indices of severity such as the Child–Turcotte–
Pugh (CTP) and Model for End Stage Liver Disease (MELD)
scores [15]. Fewer studies have examined in detail the relation-
ship between LDQOL scores and demographic and clinical vari-
ables such as age, gender, and etiology. More detailed knowledge
of the inﬂuence of these variables on LDQOL scores would be
helpful in designing future studies and in interpreting results.
The objectives of the present study are therefore to validate
the Spanish version of the LDQOL 1.0 questionnaire in pretrans-
plant liver disease patients and to analyze the impact of a range
of clinical and sociodemographic variables on LDQOL 1.0
scores.
Methods
Study Design
This was a prospective, observational, cross-sectional study
designed to validate the Spanish version of the LDQOL 1.0 in
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pretransplant patients and explore the association between clini-
cal and sociodemographic variables and HRQOL in those
patients. The study was performed in the Liver Transplant Unit
of University Hospital of Bellvitge, a large teaching hospital in
Barcelona with a well-established liver transplant program. The
patients were recruited from May 2002 to June 2006. The study
was approved by the hospital’s ethics committee and all the
patients provided informed consent to participate.
Study Population
The patients invited to participate in the study were Spanish-
speaking adults over the age of 18 with chronic liver disease who
had been accepted as candidates for liver transplantation in the
center’s Liver Transplant Unit. The patients were all outpatients
who were recruited consecutively into the study over the four-
year inclusion period. The patients with fulminant hepatic failure
or who were unable to respond to the questionnaire because of
language problems were excluded from the study.
Outcomes Measurement
The LDQOL is a disease-speciﬁc instrument designed to measure
HRQOL in patients with chronic liver disease and in liver trans-
plant candidates [7]. It consists of a 36-item generic core (the
SF-36) and 12 disease-speciﬁc scales with a further 75 items. The
SF-36 measures health status in 8 dimensions of health: physical
functioning (10 items), role limitations because of physical prob-
lems (4 items), bodily pain (2 items), general health (5 items),
energy/vitality (4 items), social functioning (2 items), role limita-
tions caused by emotional problems (3 items), and mental health/
emotional well-being (5 items). As well as scores for the
individual dimensions, the SF-36 generates two summary mea-
sures, the Physical Component Summary (PCS) scale and the
Mental Component Summary scale (MCS) [16]. The SF-36 has
been used in a number of studies in liver transplantation [6].
The 12 disease-speciﬁc scales included in the LDQOL are
liver disease-related symptoms (17 items), liver disease-related
effects on activities of daily living (10 items), concentration (7
items), memory (6 items), sexual functioning (3 items), sexual
problems (3 items), sleep (5 items), loneliness (5 items), hope-
lessness (4 items), quality of social interaction (5 items), health
distress (4 items), and self-perceived stigma of liver disease (6
items). An additional item about the use of drugs to treat insom-
nia was added to the sleep dimension in the Spanish version of
the instrument because it was considered relevant by local inves-
tigators [17]. The Spanish version of the disease-speciﬁc scales
was produced using the recommended methodology of forward
and back translation and patient testing [18], although with
input from a US Spanish version of the instrument provided by
the original authors. The SF-36 has previously been adapted and
validated for use in Spanish [19] and was incorporated directly
into the Spanish version of the LDQOL.
Disease-speciﬁc LDQOL items are answered on scales with
between four and six response options. The raw scores by dimen-
sion are recoded on a 0 to 100 scale, with higher scores indicating
better HRQOL, and dimension scores are obtained using simple
arithmetic sums. The instrument does not generate an overall
score. In most of the questions in the LDQOL, patients are asked
to think about the impact of their liver disease over the last 4
weeks, the same recall period as used in the SF-36. Although the
LDQOL 1.0 was originally designed to be self-administered, it
was administered by interview in the present study because
patients preferred this mode of administration.
When calculating LDQOL scores, we did not impute values
for missing responses, and dimension scores were therefore only
calculated for individual patients with no missing response in a
particular dimension.
Other Variables
Data collected from clinical records included age, sex, educa-
tional level, CTP class, MELD score, and etiology, which
included chronic hepatitis C (HCV), liver cirrhosis (LC) because
of alcohol liver cirrhosis (ALC), hepatocellular carcinoma
(HCC), chronic hepatitis B, primary biliary cirrhosis/primary
sclerosing cholangitis, familial amyloid polyneuropathy, Budd
Chiari syndrome, cryptogenic cirrhosis, and autoimmune hepa-
titis. The HCC patients also all had cirrhosis attributable to
another LD etiology.
The CTP score is used to assess the prognosis of chronic liver
disease, particularly cirrhosis, based on ﬁve clinical measures of
liver disease (bilirubin, serum albumin, INR, ascites, hepatic
encephalopathy). Each measure is scored from 1 to 3, with 3
indicating most severe derangement. The score is classiﬁed into
CTP class A to C by adding scores on all measures and indicating
increasingly poor prognosis [20]. Another means of classifying
liver disease patients is the MELD score, which uses serum biliru-
bin, serum creatinine, and the international normalized ratio for
prothrombin time (INR) to predict survival. The scores range
from 6 to 40. In the present study, we used the Mayo scoring
algorithm and it was analyzed as a continuous score [21].
Sample Size
A sample size of 200 was chosen to approximate the number
(n = 221) included in the original validation study and because it
was considered the maximum number that could be feasibly
included over the available four-year inclusion period.
Statistical Analysis
The sample’s sociodemographic and clinical characteristics were
analyzed using descriptive statistics. The feasibility of the Spanish
version of the LDQOL 1.0 was tested by analyzing the time taken
to administer the questionnaire and the percentage of missing
responses by dimension.
Score distributions were evaluated by calculating the
observed range of scores and the proportion of patients with the
worst and best possible scores (ﬂoor and ceiling effects) on each
dimension as an indicator of the extent to which scales capture
the range of the underlying dimension. The reliability of the
Spanish version was tested by examining the internal consistency
of each of the dimensions [22].
Validity was tested in several ways. Convergent validity was
tested by examining the extent to which scores on LDQOL
disease-speciﬁc dimensions demonstrated logical relationships
with the SF-36 based on a series of predeﬁned a priori hypotheses
[22]. We expected disease-speciﬁc scales that measure primarily
physical aspects of health (symptoms of liver disease, effects of
liver disease) to correlate more highly with the PCS and the SF-36
scales of physical functioning, role physical, bodily pain, and
general health while the LDQOL scales of concentration,
memory, quality of social interaction, health distress, loneliness,
hopelessness, and stigma of liver disease were expected to corre-
late more strongly with the MCS and the SF-36 scales of vitality,
social functioning, role emotional and mental health/emotional
well-being. We also examined correlations between the LDQOL
1.0 and MELD scores. In this case, we expected correlations to
be low to moderate (0.1–0.5) because the LDQOL is designed to
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measure a different concept to this type of clinical measure,
although some degree of correlation is expected.
Known groups’ validity was tested by determining whether
the instrument could discriminate between groups in which dif-
ferences in HRQOL would be expected to occur [22]. In particu-
lar, we examined whether the instrument could discriminate
between the patients according to CTP class and hypothesized
that the patients in CTP class A would report better HRQOL
than those in class B or C. We also examined the instrument’s
ability to discriminate between patients with different etiologies.
For this analysis, we divided the sample into four groups (HCC,
HCV, CH ALC, and others). The “others” group included all the
patients not included in the ﬁrst three groups, particularly
chronic hepatitis B, primary biliary cirrhosis/primary sclerosing
cholangitis, familial amyloid polyneuropathy, and Budd Chiari
syndrome. We hypothesized that the patients with HCC would
generally have better scores on the LDQOL than either the HCV
or CH ALC patients because liver function is often only mini-
mally impaired in the patients with HCC, while the patients with
cirrhosis have generally poorer liver functioning and overall
health [23].
Finally, and in the nature of an exploratory analysis, we
investigated the relationship between age and gender and scores
on the LDQOL.
Statistical Methods
The internal consistency of LDQOL dimensions was assessed
using Cronbach’s alpha coefﬁcient [22]. We also calculated 95%
conﬁdence intervals (CI) for the alpha coefﬁcients using a boot-
strap technique to facilitate statistical comparisons across studies
[24]. Hypotheses for convergent validity were tested using
the multitrait multimethod matrix method [25] with Pearson’s
correlation coefﬁcient (r) for normally distributed continuous
variables. Pearson’s correlation coefﬁcient was also used to inves-
tigate association between LDQOL 1.0 scores and the MELD
score and age. Spearman’s correlation coefﬁcient was used to test
for association between LDQOL scores and gender, while analy-
sis of variance (ANOVA) and t tests were used to test for differ-
ences between groups according to CTP category and etiology.
The level of statistical signiﬁcance was set at 0.05, and all tests
were two-sided. No adjustments were made for multiple com-
parisons. All analyses were performed in version 13.0 of SPSS
(SPSS Inc., Chicago, IL).
Results
Sample Characteristics
A total of 210 patients who were candidates for liver transplant
were initially approached to participate in the study, the majority
with advanced chronic liver disease. Four patients were excluded
because they had fulminant hepatitis or encephalopathy and four
because of language difﬁculties. One patient refused to partici-
pate. Of those who met the inclusion criteria who agreed to
participate, one failed to complete the study interview, leaving a
total of 200 patients for analysis.
The mean age (SD) of the patients was 52.6 (9.8) years and
73% of the sample were men (see Table 1). The most common
indication for liver transplant was HCC (34%), and 48% of the
sample had a combined etiology. All of the patients with liver
cancer also had cirrhosis: 41 because of HCV, 15 because of
alcohol, 3 because of HBV, and 9 because of other causes. For the
overall sample, the mean (SD) MELD score was 15.0 (4.9) and
69.5% were in CTP class B or C.
Feasibility
Mean (SD) time to complete the LDQOL 1.0 was 35.8 minutes
(21.2 minutes). The dimension of sexual functioning had the
largest number of missing responses (62.5% of patients with a
missing response on at least one item). This was followed by the
dimension on symptoms of liver disease (16.5% of the patients
with at least one missing response). None of the remaining
dimensions had over 7% of the patients with a missing response.
Ceiling and Floor Effects and Reliability
As shown in Table 2, ceiling effects were observed on several of
the SF-36 scales (three out of the eight scales with over 20% of
the sample scoring at the ceiling) and on the disease-speciﬁc
scales (8 of the 13 scales with over 20% of the sample scoring at
the ceiling). There were no signiﬁcant ﬂoor effects on any of the
dimensions or summary scores. The patients scored across
the full theoretical range of scores on most of the dimensions.
The internal consistency of the disease-speciﬁc dimensions of the
LDQOL was generally satisfactory, with all but two dimensions
having a Cronbach’s alpha value of 0.70 or greater. The lowest
value was for the dimension of sexual problems in women
(a = 0.64).
Convergent and Discriminant Validity
Our initial hypotheses regarding correlations between SF′36
summary scores and the disease-speciﬁc dimensions of the SF-36
were generally conﬁrmed (Table 3). The LDQOL dimensions
that measured liver disease symptoms and the effects of liver
disease correlated most strongly with the PCS (r = 0.57 and
r = 0.48, respectively), while the MCS correlated strongly with
scales that measured health distress (r = 0.66, P < 0.01), concen-
tration (r = 0.45, P < 0.01), and hopelessness (r = 0.42,
P < 0.01). Taking the two highest and two lowest correlations for
the ﬁrst 10 disease-speciﬁc dimensions, a total of 35 of the 40
correlations observed (87.5%) were in the expected direction.
For example, in the case of the health distress dimension, the two
highest correlations were with the MCS and the emotional well-
being dimension as expected, while the two lowest correlations
were with the PCS and physical functioning dimensions, also as
expected. In 5 of the 40 cases, the correlations were not as
Table 1 Sample demographic and clinical characteristics (n = 200)
N, SD (%)
Sex N (%)
Male 146 (73.0)
Age mean years (SD) 52.6, 9.8
Educational level N (%)
Primary education 93 (58.1)
Secondary education 44 (27.5)
University education 15 (9.4)
Etiology (indication liver transplant)
Tumor 68 (34.0)
Cirrhosis (alcohol) 46 (23.0)
Hepatitis C 43 (21.5)
Other (hepatitis B, PBC/colangitis; Ch cryptogenic,
FAP, Budd Chiari, Peliosis, autoimmune hepatitis)
43 (21.5)
Child–Turcotte–Pugh class N (%) 8.1, 2.1
Not applicable 20 (10.0)
A 41 (20.5)
B 86 (43.0)
C 53 (26.5)
MELD mean (SD) 15.0 (4.9)
CBP, primary biliary cirrhosis; FAP, familial amyloidotic polyneuropathy; MELD,Model for End
Stage Disease.
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expected. For example, the highest correlation for the symptoms
scale was with the SF-36 vitality dimension, whereas we had
hypothesized that the strongest correlations would be seen with
the physical dimensions. We had not made a prior hypothesis
regarding the sexual functioning dimensions as we were unsure
which direction the correlations would take.
Statistically signiﬁcant correlations with the MELD score
were seen on a number of the SF-36 dimensions, with the stron-
gest correlations being with the physical functioning summary
score (r = 0.25, P < 0.001) and the role limitation-physical
dimension (0.27, P < 0.01). Only three of the disease-speciﬁc
LDQOL dimensions showed statistically signiﬁcant correlations
with the MELD, those being the symptoms of liver disease,
effects of liver disease, and concentration dimensions, with cor-
relations of 0.29, 0.15, and 0.15, respectively (all P values 0.05
or greater).
Known Groups’ Validity
Differences in LDQOL scores by disease-speciﬁc dimensions
according to CTP class are shown in Figure 1. The patients in
CTP class A scored better than the patients in classes B and C in
almost all dimensions except loneliness. The largest differences
between the patients in class A and classes B and C were on the
Table 2 Distribution characteristics and reliability of Liver Disease Quality of Life Questionnaire (LDQOL) dimensions
LDQOL 1.0 scale
Number
of items
Mean
score
Standard
deviation
Minimum
score
Maximum
score
% Scoring
the ﬂoor
% Scoring
the ceiling
Cronbach’s a
(95% CI)
SF-36
Physical functioning 10 57.4 26.6 0.0 100.0 3.6 4.1 0.89 (0.87–0.91)
Role limitations-physical 4 29.2 37.6 0.0 100.0 52.8 15.0 0.85 (0.80–0.89)
Role limitations-emotional 3 56.3 44.3 0.0 100.0 31.8 45.3 0.87 (0.83–0.91)
Social functioning 2 65.8 31.6 0.0 100.0 4.0 33.2 0.78 (0.69–0.84)
Bodily pain 2 58.0 31.4 0.0 100.0 3.5 24.0 0.89 (0.85–0.92)
Energy/fatigue 4 44.0 28.1 0.0 100.0 7.7 2.6 0.84 (0.78–0.88)
Emotional well-being 5 61.9 26.4 0.0 100.0 2.6 9.3 0.86 (0.82–0.89)
General health 5 40.0 19.9 0.0 100.0 1.0 0.5 0.68 (0.65–0.75)
Physical component summary 36.9 10.4 14.2 64.7
Mental component summary 43.1 15.6 8.27 69.5
Disease-targeted scales
Symptoms of liver disease 17 69.4 17.9 0.0 100.0 0.5 0.5 0.76 (0.70–0.81)
Effects of liver disease 10 55.0 22.9 0.0 100.0 1.0 6.0 0.81 (0.77–0.84)
Concentration 7 74.9 24.1 0.0 100.0 1.0 22.1 0.91 (0.88–0.93)
Memory 6 78.8 21.3 0.0 100.0 0.5 22.1 0.88 (0.85–0.91)
Quality of social interaction 5 84.2 16.2 20.0 100.0 0.0 33.2 0.71 (0.63–0.77)
Health distress 4 56.1 29.3 0.0 100.0 5.5 8.0 0.87 (0.83–0.90)
Sleep 6 68.3 20.5 16.7 100.0 0.0 6.0 0.63 (0.54–0.70)
Loneliness 5 92.6 12.9 20.0 100.0 0.0 61.3 0.67 (0.50–0.76)
Hopelessness 4 70.3 22.1 6.3 100.0 0.0 14.6 0.71 (0.63–0.78)
Stigma of liver disease 6 87.4 18.3 12.5 100.0 0.0 45.7 0.78 (0.69–0.84)
Sexual functioning 3 63.9 33.1 0.0 100.0 8.6 25.8 0.85 (0.77–0.90)
Sexual problems* 3 (m) 63.8 34.6 0.0 100.0 7.1 33.9 0.82 (0.70–0.90)
3 (f) 87.0 20.8 33.3 100.0 0.0 56.5 0.64† (–)
*3 for men and 3 for women.
†It was not possible to calculate 95% CI for this value, presumably because of the low number of respondents.
Table 3 Correlation coefﬁcients between Liver Disease Quality of Life Questionnaire (LDQOL) disease-speciﬁc dimensions and SF-36 summary scales
and dimensions
LDQOL scales SF-36 scales
Disease-speciﬁc dimensions PCS MCS PF RP BP GH V SF RE EW
SxD 0.57† 0.44† 0.54† 0.52† 0.56† 0.58† 0.64† 0.53† 0.37† 0.48†
ELD 0.48† 0.38† 0.49† 0.48† 0.40† 0.56† 0.51† 0.50† 0.26† 0.48†
C 0.26† 0.45† 0.36† 0.39† 0.25† 0.41† 0.49† 0.46† 0.33† 0.48†
M 0.22† 0.29† 0.24† 0.29† 0.20† 0.30† 0.37† 0.33† 0.22† 0.29†
QSI 0.17* 0.40† 0.18† 0.26† 0.28† 0.30† 0.36† 0.40† 0.25† 0.44†
HD 0.21† 0.66† 0.34† 0.43† 0.37† 0.52† 0.53† 0.54† 0.48† 0.74†
Sle 0.32† 0.38† 0.37† 0.37† 0.28† 0.36† 0.46† 0.48† 0.24† 0.41†
Lon 0.02 0.29† 0.02 0.15* 0.15* 0.18* 0.18* 0.23† 0.22† 0.26†
Hop 0.24† 0.42† 0.32† 0.28† 0.29† 0.44† 0.43† 0.38† 0.32† 0.46†
SLD 0.17* 0.35† 0.26† 0.25† 0.21† 0.25† 0.33† 0.40† 0.25† 0.33†
Sfu 0.26† 0.22† 0.24† 0.33† 0.16* 0.27† 0.32† 0.28† 0.14 0.23†
Spro (m) 0.31* 0.35* 0.36* 0.41† 0.15 0.38† 0.40† 0.36† 0.26 0.28*
Spro (f) 0.22 0.40 0.54* 0.25 0.13 0.36 0.58† 0.56† 0.26 0.45*
*Correlation statistically signiﬁcant at P < 0.05.
†Correlation statistically signiﬁcant at P < 0.01.
Coefﬁcients marked in bold are the two highest for each LDQOL dimension. Cells marked in pale grey are the two lowest coefﬁcients for each dimension.
BP, bodily pain; C, concentration; ELD, effects of liver disease; EW, mental health/emotional well-being; GH, general health; HD, health distress; Hop, hopelessness; M, memory; MCS, Mental
component summary scale; PCS, Physical component summary scale; PF, physical functioning; QSI, quality of social interaction; RE, role limitations caused by emotional problems; RP, role
limitations because of physical problems; SF, social functioning; Sfu, sexual functioning; SLD, stigma of liver disease; Sle, sleep; Spro (f), sexual problems (female); Spro (m), sexual problems (male);
SxD, symptoms of liver disease;V, energy/vitality.
458 Casanovas et al.
symptoms dimension (mean scores of 77.8, 67.1, and 63.9,
respectively; P < 0.001 for difference between CTP-A and CTP-
C), effects of liver disease (means scores 65.9, 49.9, and 55.9,
respectively; P < 0.05 for difference between CTP-A and CTP-B),
and sexual functioning dimensions (mean scores 75.4, 63.7, and
57.0, respectively; P < 0.005 for CTP-A and CTP-C).
Table 4 shows the mean scores on all LDQOL disease-speciﬁc
dimensions according to etiology. The dimensions of symptoms,
effects of liver disease, concentration, and sleep all showed sta-
tistically signiﬁcant differences between the HCC group and the
hepatitis C group. The symptoms dimension also discriminated
between the HCC and the others group. Although results in the
other dimensions were not statistically signiﬁcant according to
the 95% CI, there was a clear tendency toward higher levels of
QOL in patients with HCC compared with those with HCV
or the group of Other pathologies. Patients in the CH ALC
group also had relatively high scores on most of the dimensions,
though with notably poorer scores in the dimension of sexual
functioning.
Effect of Age and Gender
As shown in Table 5, age was only weakly correlated with
HRQOL on two of the SF-36 dimensions (bodily pain, r = 0.156,
P < 0.05 and social functioning, r = 0.160, P < 0.05) and on 3 of
the disease-speciﬁc scales (quality of social interaction, r = 0.295,
P < 0.01; loneliness, r = 0.161, P < 0.05; and stigma of liver
disease r = 0.274, P < 0.01), with the older respondents scoring
slightly better on those ﬁve dimensions. There were statistically
signiﬁcant differences between the men and the women on three
of the disease-speciﬁc dimensions (symptoms, quality of social
interaction, and sexual functioning), with the men scoring higher
on the symptoms dimension (mean scores of 71.1 and 64.7 for
the men and women, respectively; P < 0.05) but lower on the
quality of social interaction (mean scores of 90.2 and 81.9, for
the women and men, respectively; P < 0.01) and sexual function-
ing (mean scores of 79.6 and 58.2, for the women and men,
respectively; P < 0.01) dimensions. There was a tendency toward
lower scores in the women in most of the SF-36 dimensions
though differences were not statistically signiﬁcant.
Figure 1 Differences in LDQOL scoring by disease-speciﬁc dimensions
according to CTP class. Shapes: square Child classA; triangle Child class B; circle
Child class C. LDQOL dimensions: SxD, symptoms of liver disease; ELD, effects
of liver disease; C, concentration; M, memory; QSI, quality of social interaction;
HD, health distress; Sle, sleep; Hop, Hopelessness; SLD, stigma of liver disease;
Sfu, sexual functioning; Spro (m), sexual problems (male); Spro (f), sexual prob-
lems (female).
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Discussion
This study has shown the Spanish version of the LDQOL to be a
reliable and valid instrument for use in Spanish patients with
advanced chronic liver disease awaiting transplant. In an earlier
study, we had examined the properties of the Spanish version in
post-transplant patients and found that the questionnaire was
also generally reliable in this group of patients [12]. This instru-
ment adds to disease-speciﬁc instruments already adapted for use
in Spain, such as the Chronic Liver Disease Questionnaire [26].
Although the LDQOL is a relatively long questionnaire, the
rate of missing responses was generally low, presumably at least
in part because the questionnaire was interview-administered.
The main exception was the dimension of sexual problems,
which had a high rate of missing responses primarily because a
relatively high proportion of the patients reported that they had
not had sexual relations in the past 4 weeks. Some of the patients
were also reluctant to respond to items in this dimension in the
presence of an interviewer. The questionnaire also took a con-
siderable time to administer (mean of 35.8 minutes), although it
is a very complete instrument covering a wide range of relevant
dimensions for liver disease and transplanted patients. It also
incorporates the generic SF-36, a fact which should be borne in
mind in studies where both generic and disease-speciﬁc measures
of HRQOL are required. The short version of the LDQOL
developed recently might provide a useful alternative where the
long version is impractical [10].
The LDQOL showed substantial ceiling effects on a number
of the disease-speciﬁc scales. This is likely because in a substan-
tial proportion of the sample, the primary indication for trans-
plant was HCC, and these patients have been shown to score
relatively well on generic HRQOL measures [23]. High ceiling
effects on the loneliness and quality of social interaction dimen-
sions could stem from a cultural effect because of the presence of
strong social and family networks in Spain. Comments from the
patients during cognitive debrieﬁng also indicated that the stigma
dimension may not be wholly relevant for the Spanish patients
because many found the idea of being embarrassed or self-
conscious about the disease unusual and alien. The dimensions of
loneliness, hopelessness, stigma, sexual functioning, and sexual
problems also showed the highest ceiling effects in the original
version (18.7%, 12.3%, 18.2%, 24.3%, and 24.1% [7]), sug-
gesting that the items included may not adequately capture the
full range of effects and/or that the dimensions may not be as
relevant to patients as some others. Such effects are important as
they may affect the instrument’s ability to reﬂect improvement
over time.
With regard to the high ceiling effect seen on the sexual
problems (women) scale, this may have been due to a reluctance
to acknowledge problems in this area of their lives with an
interviewer present. It is also possible that scale items were not
relevant for the entire sample for the time period covered (4
weeks) because frequency of sexual intercourse has been shown
to decrease in women with nonalcoholic liver disease [27].
However, we were not able to ascertain whether this was the case
in our sample, although this is certainly an aspect of using the
LDQOL that would warrant further research.
In terms of reliability, the Spanish version of the LDQOL was
generally satisfactory in the present study. The Cronbach’s alpha
values were over the recommended 0.70 threshold [28] for 8 of
the 12 disease-speciﬁc dimensions, and close to 0.70 on the
remaining dimensions. On the SF-36, the 0.70 threshold was met
on all but one of the eight dimensions. This means the LDQOL
is suitable for use at the group level; very few of the dimensions,
however, had an alpha value of 0.90 or over so they would not be
suitable for use with patients at an individual level. Interestingly,
the four dimensions that showed the poorest results on Cron-
bach’s alpha in the present study also had some of the lowest
Table 5 Effect of age and gender on LDQOL scores
LDQOL scales
Age Gender
N r P value
Men Women
P valueN Mean (SD) N Mean (SD)
SF-36 scales
Physical functioning 197 -0.065 NS 144 58.6 (26.3) 53 54.1 (27.4) NS
Role limitation-physical 193 0.119 NS 141 29.7 (37.4) 52 27.9 (38.6) NS
Bodily pain 200 0.156* <0.05 146 60.4 (31.5) 54 51.4 (30.5) NS
General Health perceptions 195 0.084 NS 142 40.9 (19.5) 53 39.4 (21.1) NS
Mental Health 193 0.104 NS 140 64.0 (25.7) 53 56.2 (27.7) NS
Role limitation-emotional 192 0.101 NS 141 58.4 (44.4) 51 50.3 (43.9) NS
Social functioning 199 0.160* <0.05 146 68.2 (31.1) 53 59.2 (32.3) NS
Vitality/energy/fatigue 195 0.085 NS 141 45.7 (27.6) 54 39.6 (29.4) NS
Physical summary score 186 0.059 NS 136 37.0 (9.8) 50 36.6 (11.8) NS
Mental summary score 186 0.136 NS 136 44.2 (15.3) 50 40.1 (16.3) NS
Liver disease targeted scales
Symptoms of liver disease 200 0.046 NS 146 71.1 (17.6) 54 64.7 (17.9) <0.05
Effects of liver disease 200 0.059 NS 146 55.2 (23.2) 54 54.4 (22.1) NS
Concentration 199 0.075 NS 145 75.0 (24.1) 54 74.6 (24.1) NS
Memory 199 0.051 NS 145 77.7 (21.7) 54 81.7 (20.1) NS
Quality of social interaction 199 0.295† <0.01 145 81.9 (16.7) 54 90.2 (12.9) <0.001
Health distress 199 0.128 NS 145 57.8 (29.4) 54 51.7 (28.9) NS
Sleep 199 0.102 NS 145 67.6 (20.3) 54 70.1 (21.0) NS
Loneliness 199 0.161* <0.05 145 91.8 (13.7) 54 94.6 (10.3) NS
Hopelessness 199 0.056 NS 145 69.7 (22.2) 54 71.6 (22.1) NS
Stigma of liver disease 199 0.274† <0.01 145 86.8 (19.5) 54 88.8 (14.6) NS
Sexual functioning 198 0.097 NS 145 58.2 (33.7) 53 79.6 (25.8) <0.001
Sexual problems (m) 56 0.063 NS — — — — —
Sexual problems (f) 23 -0.263 NS — — — — —
*Correlation signiﬁcant at 0.05 (2-tailed).
†Correlation signiﬁcant at 0.01 (2-tailed).
r, Pearson’s correlation coefﬁcient.
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alphas on the original version, although they were all over the
threshold of 0.70 except for quality of social interaction [7].
Further work may be required to bolster reliability in these
scales.
In the development of the original LDQOL, factor analysis
was used to investigate the scale structure of that version [7]. In
the present study, as our aim was to determine whether the
Spanish instrument would be sufﬁciently reliable and valid for
use in research settings, we preferred to investigate whether the
LDQOL dimensions formed coherent scales through the calcu-
lation of Cronbach’s alpha. As all of the alphas for the disease-
speciﬁc dimensions were very close to or above 0.70, which is the
generally recommended threshold for use of this type of instru-
ment at group level [28], we considered that to be a sufﬁcient
indication of reliability to suggest that the instrument could be
used in research settings in Spain.
Likewise, it should be noted that all of the interviews were
carried out by the same psychologist who was involved in the
study from the outset (LJC), so interrater reliability was not an
issue here. However, this would be an aspect that would warrant
research in future studies.
With regard to convergent validity, we found that the
LDQOL disease-speciﬁc dimensions correlated as expected with
individual SF-36 dimensions and summary scores. Correlations
were particularly strong between LDQOL 1.0 disease-speciﬁc
dimensions and the MCS and SF-36 dimensions that measure
psychological and social functioning, indicating the considerable
focus on psychological and emotional aspects of the illness in the
LDQOL 1.0. Only a small number of the hypotheses regarding
the likely pattern of correlations were not met, and the deviations
from the hypotheses were generally minor, suggesting good con-
vergent validity for the Spanish measure.
On the other hand, correlations with the MELD score were
generally low to moderate, although strongest with the physical
functioning dimensions of the SF-36. This likely reﬂects the
aspects measured by the MELD and is similar to ﬁndings
observed with the original version of the instrument [15]. Like-
wise, we found that the dimensions that best discriminated
between groups deﬁned by the CTP category were symptoms of
liver disease, effects of liver disease, and sexual functioning,
which also showed some of the strongest correlations with the
CTP score in the original validation study [7], although correla-
tions between clinician-derived measures and HRQOL have gen-
erally been found to be weak [15,29]. The fact that sexual
problems did not discriminate well between the groups in our
study may be due to the high number of missing responses.
Our analysis of the known groups’ validity suggests that a
number of dimensions on the LDQOL Spanish version distin-
guished adequately between the patients deﬁned by clinical cat-
egories. In particular, the instrument was successful at
discriminating between the patients deﬁned by CTP class (see
Fig. 1), although we also found that HCV was associated with
considerably worse HRQOL on most of the LDQOL disease-
speciﬁc dimensions than either HCC or LC ALC. Although these
differences were only statistically signiﬁcant on four dimensions
(symptoms, effects of liver disease, concentration, and sleep),
they are nevertheless in line with results from similar studies that
showed that patients with HCV tend to have worse HRQOL
than patients with other etiologies [30,31]. The present results
also complement those found in previous studies that found
differences between cirrhotic and noncirrhotic patients [32].
On the other hand, our analysis of the effect of sociodemo-
graphic variables showed that age and gender generally had only
a small effect on LDQOL 1.0 scores. The poorer score on the
social interaction dimension in men may be due to the disease
leading to greater restrictions on social activities or a tendency to
be more withdrawn, perhaps because of a greater impact on
self-image though this has been little explored in the literature.
The poorer score in men on the sexual functioning dimension
does receive some support in the literature, which suggests that
men with CTP grades B and C have signiﬁcant sexual dysfunc-
tion and signiﬁcant reduction of both total and free testosterone
levels [33]. This contrasts with ﬁndings in women that suggest
that liver disease does not have a signiﬁcant impact on sexual
satisfaction or desire [27,34].
In general, the results of validity testing support the use of the
instrument in future studies in Spain, although further testing is
still required in larger, more heterogeneous samples, and in lon-
gitudinal studies to test the instrument’s sensitivity to change.
Likewise, additional information, such as the magnitude of a
minimal clinically relevant difference on the different dimensions
would help to improve interpretability [35].
The study had some limitations. Firstly, although the sample
was relatively large, the study was performed in only one center
and the sample included a high proportion of HCC and male
patients. Both of these characteristics limit the generalizability of
the results. The inclusion of a large number of HCC cases reﬂects
the case mix on the waiting list at this center [36]. It should also
be noted that at least some of the impact on HRQOL is likely to
be due to the underlying cirrhosis rather than the tumor itself,
which tends to be asymptomatic. The questionnaire was admin-
istered by interview and the results might differ if the question-
naire was self-administered. Future studies should examine
whether there are systematic differences in the scores using the
two different modes of administration. Finally, we were not able
to examine the instrument’s sensitivity to change as these are
results from a cross-sectional study. Analysis of this aspect is
currently ongoing for the Spanish version of the LDQOL. Finally,
we did not impute values for missing responses as the proportion
of missing responses was low in most of the scales, and they were
not concentrated in particular items within the scales. In the
present study, the relatively small proportion of missing
responses would not have overly biased results. However, if
higher proportions of missing responses are observed or if they
are more systematic, then other methods of imputing scores
should be considered, such as simple mean imputation, or more
sophisticated techniques such as regression imputation [37].
In conclusion, the Spanish version of the LDQOL 1.0 pro-
vides a reliable and valid means of measuring outcomes in
patients with liver disease awaiting transplant. The fact that it is
a very complete instrument means that administration time is
considerable and the new, shorter version may prove more prac-
tical for much clinical research or clinical practice. The consid-
erable ceiling effects on a number of dimensions also suggest
its performance in longitudinal studies should be carefully
evaluated.
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